TRENTON, N.J.--(BUSINESS WIRE)-- <\/p>\n
BioNJ, the trade association for New Jersey\u2019s biotechnology industry, will host its biggest and most interactive event to date for companies involved in diagnostics and personalized medicine on March 14, 2012 at Princeton University. The BioNJ Diagnostics & Personalized Medicine Innovation Summit and Funding Roundtable, part of BioNJ\u2019s ongoing Diagnostics & Personalized Medicine Initiative, will bring together leaders from major global biotechnology and pharmaceutical companies, diagnostics companies and emerging \u201cinnovator\u201d companies for a half-day, interactive summit meeting. <\/p>\n
The focus of this half-day summit is to help participants identify opportunities for partnership, funding and growth while updating them on the latest trends, developments and challenges in the evolution and adoption of personalized medicine. All companies and individuals with an interest in diagnostics and personalized medicine are welcome to attend this event. The Summit will include company presentations and opportunities for one-on-one communication and interaction between leading global pharmaceutical companies, emerging diagnostics companies, funding organizations and life sciences company business development professionals. <\/p>\n
\u201cThis event promises to be truly unique for those who attend,\u201d said Debbie Hart, President of BioNJ. \u201cNot only have we confirmed first-class speakers from all key constituencies involved with diagnostics and personalized medicine, we will also create opportunities for global life science leaders, smaller innovators and members of the investment community to network and establish partnerships that will advance the development and utilization of personalized medicine worldwide.\u201d <\/p>\n
Speaking at the Summit will be leaders from the global investment community, global life sciences companies and academia: <\/p>\n
G. Steven Burrill
Chief Executive Officer, Burrill & Company <\/p>\n
Joseph P. Hammang, Ph.D.
Senior Director, Worldwide Science Policy, Pfizer Inc. <\/p>\n
Paul Kildal-Brandt
Global Alliance Leader, Janssen Diagnostics <\/p>\n
Aydogan Ozcan, Ph.D.
The Scientist's Top Innovation Award Winner of 2011
Associate Professor, UCLA
Electrical Engineering & Bioengineering Department <\/p>\n
The BioNJ Diagnostics and Personalized Medicine Committee, which created the BioNJ Diagnostics & Personalized Medicine Innovation Summit and Funding Roundtable, is also planning additional events focusing on diagnostics and personalized medicine, and will be announcing details for future events on its website. <\/p>\n
\u201cThe increasing interest in diagnostics and personalized medicine, and its potential to transform medicine, is clear from the participation in the events that the BioNJ Diagnostics and Personalized Medicine Committee has offered so far,\u201d said Steve Carchedi, Committee Co-Chair, Chief Marketing Officer, Medical Diagnostics, GE Healthcare. \u201cThe BioNJ Diagnostics & Personalized Medicine Innovation Summit and Funding Roundtable will be our biggest event ever, and I encourage anyone with an interest in diagnostics and personalized medicine to join us on March 14th at Princeton University,\u201d he added. <\/p>\n
About the BioNJ Diagnostics Committee <\/p>\n
The BioNJ Diagnostics and Personalized Medicine Committee was created to advance personalized medicine through diagnostics by identifying and supporting partnerships with industry, academic, government and investors in the State of New Jersey. <\/p>\n
The goal of the committee is to define and accelerate new areas of diagnostics, such as in vivo and in vitro tests, biomarkers, imaging, information systems and other innovative technologies. <\/p>\n
About BioNJ <\/p>\n
With more than 300 member companies, BioNJ is singularly focused on the growth and prosperity of New Jersey\u2019s biotechnology cluster. Founded in 1994 by New Jersey industry CEOs, BioNJ serves as the voice of biotechnology companies located in New Jersey, seeks to advance their economic growth and development and works to encourage new and established companies from around the world to locate to New Jersey. BioNJ represents companies engaged in biopharmaceutical, biomedical, bioagricultural and bioremedial endeavors. <\/p>\n<\/p>\n
Go here to see the original: TRENTON, N.J.--(BUSINESS WIRE)-- BioNJ, the trade association for New Jersey\u2019s biotechnology industry, will host its biggest and most interactive event to date for companies involved in diagnostics and personalized medicine on March 14, 2012 at Princeton University. The BioNJ Diagnostics & Personalized Medicine Innovation Summit and Funding Roundtable, part of BioNJ\u2019s ongoing Diagnostics & Personalized Medicine Initiative, will bring together leaders from major global biotechnology and pharmaceutical companies, diagnostics companies and emerging \u201cinnovator\u201d companies for a half-day, interactive summit meeting Continue reading
\nBioNJ Diagnostics & Personalized Medicine Innovation Summit and Funding Roundtable Taking Place at Princeton University<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"